BrainChild Bio Secures $300K Grant for Breakthrough Pediatric Brain Cancer CAR-T Therapy Development
Summary
The G-Rex\xae Grant will support expeditious process development and commercial readiness of BCB-276, BrainChild Bios lead autologous CAR-T therapy for the treatment of diffuse intrinsic pontine glioma (DIPG), an incurable type of pediatric brain tumor. BrainChild Bio plans to advance BCB-276 into a multi-center Phase 2 pivotal clinical trial in 2025 for the treatment of children and young adults with DIPG. Its an honor for our team to be able to help accelerate BrainChilds novel BCB-276 treatment for brain tumors to those in need and this program is perfectly aligned with our goal of bringing hope to cancer patients," said John Wilson, CEO of Wilson Wolf Manufacturing Corporation and co-inventor of G-Rex.As part of the G-Rex Grant, BrainChild Bio will perform process development and optimization of their G-Rex based CAR-T cell manufacturing process in anticipation of a pivotal clinical trial. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.Wilson Wolfs mission is to create hope for cancer patients, one G-Rex\xae device at a time.About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. The company offers a wide range of services to support the development and commercialization of these therapies.CellReadys mission is to create hope for cancer patients, one G-Rex\xae process at a time.About BrainChild BioBrainChild Bio, Inc., is a kids-first, clinical-stage biotechnology company harnessing the power of CAR T-cell technology to treat tumors in the central nervous system, prioritizing pediatric indications with plans to expand into adult CNS tumors, specifically Glioblastoma and Brain Metastasis.